Johnson & Johnson reports 35% Crohn's fistula remission
Share
Johnson & Johnson (NYSE:JNJ) reported 35% combined fistula remission at Week 48 with TREMFYA in its Phase 3 FUZION Crohn's disease trial.
Johnson & Johnson (NYSE:JNJ) reported 35% combined fistula remission at Week 48 with TREMFYA in its Phase 3 FUZION Crohn's disease trial.
Johnson & Johnson Chairman & CEO Joaquin Duato says artificial intelligence is a force multiplier and has to be embraced. He's on this week's episode of The David Rubenstein Show: Peer to Peer Conversations. This interview was recorded on June 16 in Washington.
Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 results with sales increasing 5.9% to $25.4 billion, supported by operational growth of 6.0% and adjusted operational growth of 6.1%.
Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.
Johnson & Johnson (NYSE:JNJ) reported two-year Phase 3 ICONIC-LEAD results showing at least 72% of ICOTYDE-treated patients achieved PASI 90 at Week 112.
Johnson & Johnson (NYSE:JNJ) offered $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and other talc products caused ovarian cancer.
